Last reviewed · How we verify

Fludarabine, Busulfan, Thymoglobulin

The Korean Society of Pediatric Hematology Oncology · Phase 2 active Small molecule

Fludarabine, Busulfan, Thymoglobulin is a Purine analog, Alkylating agent, Monoclonal antibody Small molecule drug developed by The Korean Society of Pediatric Hematology Oncology. It is currently in Phase 2 development for Acute myeloid leukemia, Chronic lymphocytic leukemia, Kidney transplant rejection.

Fludarabine is a purine analog that interferes with DNA synthesis, Busulfan is an alkylating agent that cross-links DNA, and Thymoglobulin is a monoclonal antibody that depletes T-lymphocytes.

Fludarabine is a purine analog that interferes with DNA synthesis, Busulfan is an alkylating agent that cross-links DNA, and Thymoglobulin is a monoclonal antibody that depletes T-lymphocytes. Used for Acute myeloid leukemia, Chronic lymphocytic leukemia, Kidney transplant rejection.

At a glance

Generic nameFludarabine, Busulfan, Thymoglobulin
SponsorThe Korean Society of Pediatric Hematology Oncology
Drug classPurine analog, Alkylating agent, Monoclonal antibody
TargetDNA, CD3 receptors
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Fludarabine works by incorporating itself into DNA and interfering with DNA synthesis, leading to cell death. Busulfan works by cross-linking DNA, which prevents cancer cells from replicating. Thymoglobulin works by binding to CD3 receptors on T-lymphocytes and marking them for destruction, leading to a decrease in T-cell count.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fludarabine, Busulfan, Thymoglobulin

What is Fludarabine, Busulfan, Thymoglobulin?

Fludarabine, Busulfan, Thymoglobulin is a Purine analog, Alkylating agent, Monoclonal antibody drug developed by The Korean Society of Pediatric Hematology Oncology, indicated for Acute myeloid leukemia, Chronic lymphocytic leukemia, Kidney transplant rejection.

How does Fludarabine, Busulfan, Thymoglobulin work?

Fludarabine is a purine analog that interferes with DNA synthesis, Busulfan is an alkylating agent that cross-links DNA, and Thymoglobulin is a monoclonal antibody that depletes T-lymphocytes.

What is Fludarabine, Busulfan, Thymoglobulin used for?

Fludarabine, Busulfan, Thymoglobulin is indicated for Acute myeloid leukemia, Chronic lymphocytic leukemia, Kidney transplant rejection.

Who makes Fludarabine, Busulfan, Thymoglobulin?

Fludarabine, Busulfan, Thymoglobulin is developed by The Korean Society of Pediatric Hematology Oncology (see full The Korean Society of Pediatric Hematology Oncology pipeline at /company/the-korean-society-of-pediatric-hematology-oncology).

What drug class is Fludarabine, Busulfan, Thymoglobulin in?

Fludarabine, Busulfan, Thymoglobulin belongs to the Purine analog, Alkylating agent, Monoclonal antibody class. See all Purine analog, Alkylating agent, Monoclonal antibody drugs at /class/purine-analog-alkylating-agent-monoclonal-antibody.

What development phase is Fludarabine, Busulfan, Thymoglobulin in?

Fludarabine, Busulfan, Thymoglobulin is in Phase 2.

What are the side effects of Fludarabine, Busulfan, Thymoglobulin?

Common side effects of Fludarabine, Busulfan, Thymoglobulin include Nausea, Vomiting, Diarrhea, Fatigue, Infection.

What does Fludarabine, Busulfan, Thymoglobulin target?

Fludarabine, Busulfan, Thymoglobulin targets DNA, CD3 receptors and is a Purine analog, Alkylating agent, Monoclonal antibody.

Related